Literature DB >> 29336904

Bypass versus endovascular intervention for healing ischemic foot wounds secondary to tibial arterial disease.

Abhisekh Mohapatra1, Jon C Henry2, Efthimios D Avgerinos2, Aureline Boitet2, Rabih A Chaer2, Michel S Makaroun2, Steven A Leers2, Eric S Hager2.   

Abstract

OBJECTIVE: Pedal (inframalleolar) bypass is a long-standing therapy for tibial arterial disease in patients with ischemic tissue loss. Endovascular tibial intervention is an appealing alternative with lower risks of perioperative mortality or complications. Our objective was to compare the effectiveness of these two treatment modalities with respect to patency and limb-related clinical outcomes.
METHODS: We performed a retrospective chart review of patients presenting between 2006 and 2013 with ischemic foot wounds and infrapopliteal arterial disease who underwent a revascularization procedure (either open surgical bypass to an inframalleolar target or endovascular tibial intervention). Data were collected on baseline demographics and comorbidities, procedural details, and postprocedure outcomes. The primary outcome was successful healing of the index wound, with mortality, major amputation, and patency assessed as secondary outcomes.
RESULTS: We identified 417 patients who met our eligibility criteria; 105 underwent surgical bypass and 312 underwent endovascular intervention, with mean follow-up of 25.0 and 20.2 months, respectively (P = .08). The endovascular patients were older at baseline (P = .009), with higher rates of hyperlipidemia (P = .02), prior cerebrovascular accidents (P = .04), and smoking history (P = .04). Within 30 days postoperatively, there was no difference in mortality (P = .31), but bypass patients had longer hospital length of stay (P < .0001), higher rate of discharge to nursing facility (P < .001), and higher rates of myocardial infarctions (P = .03) and wound complications (P < .001). At 6 months, the rate of wound healing was 22.4% in the bypass group compared with 29.0% in the endovascular group (P = .02). At 1 year, survival was higher after bypass (86.2% vs 70.4%; P < .0001), but freedom from major amputation was similar (84.9% vs 82.8%; P = .42). Primary patency (53.1% vs 38.2%; P = .002) and primary assisted patency (76.6% vs 51.7%; P < .0001) were higher in the bypass group, but there was no difference in secondary patency (77.3% vs 73.8%; P = .13).
CONCLUSIONS: Endovascular tibial intervention is associated with poorer primary patency but similar secondary patency and wound healing rates compared with the "gold standard" of surgical bypass to a pedal target. In patients with tibial arterial disease, endovascular intervention should be considered a lower risk alternative to pedal bypass that provides similar clinical outcomes.
Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29336904      PMCID: PMC6019116          DOI: 10.1016/j.jvs.2017.10.076

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  23 in total

Review 1.  Patterns of disease distribution of lower extremity peripheral arterial disease.

Authors:  Qian Chen; Yang Shi; Yutang Wang; Xiaoying Li
Journal:  Angiology       Date:  2014-03-19       Impact factor: 3.619

Review 2.  Endovascular Treatment of Infrapopliteal Peripheral Artery Disease.

Authors:  Ehrin J Armstrong; Kalkidan Bishu; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

Review 3.  Diabetic revascularization: endovascular versus open bypass--do we have the answer?

Authors:  Michael S Conte
Journal:  Semin Vasc Surg       Date:  2012-06       Impact factor: 1.000

4.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.

Authors:  Kenneth Rosenfield; Michael R Jaff; Christopher J White; Krishna Rocha-Singh; Carlos Mena-Hurtado; D Christopher Metzger; Marianne Brodmann; Ernst Pilger; Thomas Zeller; Prakash Krishnan; Roger Gammon; Stefan Müller-Hülsbeck; Mark R Nehler; James F Benenati; Dierk Scheinert
Journal:  N Engl J Med       Date:  2015-06-24       Impact factor: 91.245

5.  Angioplasty versus bypass surgery in patients with critical limb ischemia-a meta-analysis.

Authors:  Xiaoyang Fu; Zhidong Zhang; Kai Liang; Shuaitao Shi; Guoquan Wang; Kewei Zhang; Kun Li; Weixiao Li; Tianxiao Li; Shuiting Zhai
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease.

Authors:  Alessia Giaquinta; Ardita Vincenzo; Ester De Marco; Massimiliano Veroux; Pierfrancesco Veroux
Journal:  Vasc Endovascular Surg       Date:  2017-01-18       Impact factor: 1.089

7.  Costs of Real-Life Endovascular Treatment of Critical Limb Ischemia: Report from Poland-A European Union Country with a Low-Budget Health Care System.

Authors:  Marek Krzanowski; Lukasz Drelicharz; Andrzej Belowski; Lukasz Partyka; Barbara Sumek-Brandys; Piravin Kumar Ramakrishnan; Rafal Nizankowski
Journal:  Ann Vasc Surg       Date:  2015-11-23       Impact factor: 1.466

8.  Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.

Authors:  Gunnar Tepe; John Laird; Peter Schneider; Marianne Brodmann; Prakash Krishnan; Antonio Micari; Christopher Metzger; Dierk Scheinert; Thomas Zeller; David J Cohen; David B Snead; Beaux Alexander; Mario Landini; Michael R Jaff
Journal:  Circulation       Date:  2014-12-03       Impact factor: 29.690

9.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.

Authors:  Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Lindsay S Machan; Scott A Snyder; Erin E O'Leary; Anthony O Ragheb; Thomas Zeller
Journal:  Circulation       Date:  2016-03-11       Impact factor: 29.690

10.  Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial.

Authors:  Matthew A Popplewell; Huw Davies; Hugh Jarrett; Gareth Bate; Margaret Grant; Smitaa Patel; Samir Mehta; Lazaros Andronis; Tracy Roberts; Jon Deeks; Andrew Bradbury
Journal:  Trials       Date:  2016-01-06       Impact factor: 2.279

View more
  1 in total

1.  The short- and long-term efficacies of endovascular interventions for the treatment of acute ischemic stroke patients.

Authors:  Xingxiu Yang; Xiaohui Jia; Hua Ren; Hongxing Zhang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.